Culture-adapted  isolates from UK travellers:  drug sensitivity, clonality and drug resistance markers by unknown
van Schalkwyk et al. Malaria Journal 2013, 12:320
http://www.malariajournal.com/content/12/1/320RESEARCH Open AccessCulture-adapted Plasmodium falciparum isolates
from UK travellers: in vitro drug sensitivity,
clonality and drug resistance markers
Donelly A van Schalkwyk1†, Rebekah Burrow1†, Gisela Henriques1, Nahla B Gadalla1, Khalid B Beshir1,
Christian Hasford2, Stephen G Wright3, Xavier C Ding4, Peter L Chiodini3 and Colin J Sutherland1,3*Abstract
Background: The screening of lead compounds against in vitro parasite cultures is an essential step in the
development of novel anti-malarial drugs, but currently relies on laboratory parasite lines established in vitro during
the last century. This study sought to establish in continuous culture a series of recent Plasmodium falciparum
isolates to represent the current parasite populations in Africa, all of which are now exposed to artemisinin
combination therapy.
Methods: Pre-treatment P. falciparum isolates were obtained in EDTA, and placed into continuous culture after
sampling of DNA. One post-treatment blood sample was also collected for each donor to monitor parasite clonality
during clearance in vivo. IC50 estimates were obtained for 11 anti-malarial compounds for each established parasite
line, clonal multiplicity measured in vivo and in vitro, and polymorphic sites implicated in parasite sensitivity to
drugs were investigated at the pfmdr1, pfcrt, pfdhfr, pfdhps and pfap2mu loci before and after treatment, and in the
cultured lines.
Results: Plasmodium falciparum isolates from seven malaria patients with recent travel to three West African and
two East African countries were successfully established in long-term culture. One of these, HL1211, was from a
patient with recrudescent parasitaemia 14 days after a full course of artemether-lumefantrine. All established culture
lines were shown to be polyclonal, reflecting the in vivo isolates from which they were derived, and at least two
lines reliably produce gametocytes in vitro. Two lines displayed high chloroquine IC50 estimates, and carried the
CVIET haplotype at codons 72–76, whereas the remaining five lines carried the CVMNK haplotype and were
sensitive in vitro. All were sensitive to the endoperoxides dihydroartemisinin and OZ277, but IC50 estimates for
lumefantrine varied, with the least sensitive parasites carrying pfmdr1 alleles encoding Asn at codon 86.
Conclusions: This study describes the establishment in continuous culture, in vitro drug sensitivity testing and
molecular characterization of a series of multiclonal P. falciparum isolates taken directly from UK malaria patients
following recent travel to various malaria-endemic countries in Africa. These “HL” isolates are available as an open
resource for studies of drug response, antigenic diversity and other aspects of parasite biology.* Correspondence: colin.sutherland@lshtm.ac.uk
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There are currently six species of the genus Plasmodium
known to infect humans: Plasmodium falciparum, Plas-
modium vivax, Plasmodium ovale curtisi, Plasmodium
ovale wallikeri, Plasmodium malariae and Plasmodium
knowlesi [1,2]. Of these, P. falciparum is the species re-
sponsible for most of the mortality and morbidity associ-
ated with the disease and it is during the asexual intra-
erythrocytic stages that most of the symptoms of malaria
are manifest. Studies into many aspects of human mal-
aria parasite biology were greatly advanced by the devel-
opment of a method to culture asexual blood stages of
P. falciparum in vitro in 1976 [3]. Since then, several
parasite strains and clones have been cultivated from vary-
ing geographical regions, allowing researchers to explore
differences in parasite phenotypes as diverse as immune
evasion in mosquitoes [4] and red cell invasion [5] to the
development of drug resistance [6,7]. However, the most
widely studied in vitro parasite strains or clones have been
in use for more than two decades (Table 1) and therefore
pre-date the era of widespread artemisinin-based combin-
ation therapy (ACT) implementation. In addition, many of
these parasite lines originate from Asia or the Americas
(Table 1). However, it is in Africa where the majority of
deaths from malaria are reported, and the greatest trans-




3D7 (cloned from NF-54) Netherlands
D10 (cloned from FC27) Papua New Guinea
HB3 (cloned from Honduras I/CDC) Honduras
D6 (cloned from Sierra Leone I/CDC) Sierra Leone
T9-96 (cloned from T9) Thailand
GB4 (cloned from Ghana III/CDC) Ghana




W2 (cloned from Indo III/CDC) Indochina
W2mef (derived from W2) Indochina
Dd2 (cloned from W2mef) Indochina
7G8 (cloned from IMTM22) Brazil
V1/S (cloned from V1) Vietnam
Malayan Camp Malaya
§This list is not meant to reflect an exhaustive reference of all the parasite lines in u
cross or the 7G8 × GB4 genetic cross. Instead, it represents a list of parasites that pr
sensitivity studies.
*These are the earliest literature reports for the parasite lines/clones listed so the acthe infection from which the parasites lines were isolated
(i e, possible parasite drug exposure from prophylaxis, pa-
tient travel histories, etc.) is not easy to access, if at all
available.
Since 2001 the World Health Organization (WHO)
has recommended ACT as first-line treatment for un-
complicated P. falciparum malaria infections [26]. ACT
involves pairing an artemisinin derivative, with its
short elimination half-life, with a longer-lasting anti-
malarial partner drug (e g, artemether-lumefantrine,
dihydroartemisinin-piperaquine, etc.). This approach to
treatment has been highly successful for several years
in areas where drug resistance to chloroquine or
sulphadoxine-pyrimethamine had been widespread [27].
However, an increasing number of infections exhibiting re-
duced sensitivity to artemisinin in vivo are being observed
in areas of western Cambodia, Thailand and recently south-
ern Myanmar [28-32]. This has been attributed to a delayed
clearance phenotype with recent evidence suggesting that
parasites have developed a mechanism that allows them to
remain dormant in the ring stage of their life cycle in order
to evade the toxic effects of the short half-life artemisinin
derivative [33,34]. This developing altered phenotype high-
lights a need to update in vitro parasite lines in order to
study parasites whose behaviour reflect the current anti-
malarial exposure patterns.t widespread use for in vitro studies














South America 1984 [23]
Asia 1990 [24]
Asia 1965 [25]
se world-wide and it excludes the multiple progeny of the HB3 × Dd2 genetic
edominate in the literature still today in several genetic and drug
tual date of establishment in culture pre-dates these references in each case.
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parasites with reduced susceptibility to artemisinin, but
persistent parasitaemia after treatment with artemether-
lumefantrine has been associated with particular alleles of
pfmdr1 in vivo [35]. Recent published data from studies of
artemisinin resistance in the rodent parasite Plasmodium
chabaudi has identified a new candidate locus, pcap2mu,
encoding the clathrin-associated μ adaptor protein 2 [36].
These authors described potentially important se-
quence diversity in the P. falciparum homologue,
pfap2mu (PF3D7_1218300), between codons 146 and
437, in a series of clinical isolates.
The aim of this study was to establish a fully character-
ized panel of recent P. falciparum isolates, adapted to
grow under standard in vitro culture conditions, for stud-
ies of sensitivity to both established and investigational
anti-malarial drugs. This small series of newly culture-
adapted P. falciparum isolates, together with relevant
genotyping analysis at loci of interest and drug response
phenotypes, has been made available as a resource for re-
searchers wishing to work in vitro with African parasites
from the current ACT era.
Methods
Patient sample acquisition
Voluntary consent and travel history was obtained from pa-
tients presenting with malaria to the Hospital for Tropical
Diseases, London (HTD), or the Accident and Emer-
gency Department of University College London Hospi-
tals (UCLH). A venous blood sample was obtained in a
4 mL Vacutainer tube containing EDTA (BD, Oxfordshire,
UK). A few drops of blood were removed to prepare thick
and thin blood smears in order to confirm diagnosis and to
establish parasitaemia. A 200 μL aliquot of whole blood
was removed for DNA extraction for use in later genotyp-
ing assays. The remaining sample was then used for the la-
boratory adaptation of the malaria parasites in the malaria
culture laboratories, London School of Hygiene & Tropical
Medicine (LSHTM). All patient identifiers were removed
and a code assigned to each parasite sample. Approval for
the study was obtained from the Research Ethics Commit-
tee of the University College London Hospitals (Application
number: 07/Q0505/60). All seven patients described herein
were managed as in-patients, with fully observed antimalar-
ial treatment. Those treated with AL received the standard
dosage of Riamet© as recommended by the manufacturer
(Novartis Pharmaceuticals UK Ltd), which comprises six
doses of four tablets each, taken over 60 hours. Each tablet
contains 20 mg artemether and 120 mg lumefantrine.
General reagents and compounds for growth
inhibition studies
Albumax II and gentamicin sulphate were purchased from
Invitrogen (Carlsbad, CA, USA). HEPES, RPMI 1640,human AB serum, hypoxanthine, L-glutamine and D-
glucose were purchased from Sigma-Aldrich (St Louis,
MO, USA). Anti-malarial compounds/drugs used in this
study were supplied by the Medicines for Malaria Venture
(MMV, Geneva, Switzerland). Primary stock solutions for
all compounds, except chloroquine, were first made by
dissolution in dimethyl sulphoxide (DMSO). Subsequent
dilutions were made in complete RPMI growth media
such that the amount of DMSO present in the test con-
centration range was non-toxic to parasites. Chloroquine
primary stocks were made by dissolution in deionized
water (Millipore, Watford, UK).
Laboratory adaptation and parasite culture
The whole blood sample obtained from the patients was
first washed twice in RPMI growth media in order to sep-
arate the red cells from the plasma. Briefly, the whole
blood was suspended in 6 mL of RPMI media and
centrifuged at 2,000 × g for 10 min. The supernatant and
buffy coat were then removed and the red cell pellet was
suspended in approximately 8 mL of RPMI before a second
centrifugation step as described above. After removing the
supernatant the parasitized red cells were resuspended in
complete medium (CM) for culture adaptation. For the
first isolate obtained (HL1204) this was composed of RPMI
1640 growth medium supplemented with 10% (v/v) human
AB serum, 25 mg/L gentamicin, 147 μM hypoxanthine,
25 mM HEPES, and 25 mM Na2HCO3. For all subsequent
isolate adaptation and routine parasite cultivation the
amount of human serum added was reduced to 2% (v/v)
and the CM further supplemented with 5 g/L Albumax II,
10 mM D-glucose and 2 mM L-glutamine. The parasites
were maintained in continuous culture with shaking. The
parasites were stored in a sealed flask incubated at 37°C
under a gas mixture of 93% N2, 4% CO2 and 3% O2. As the
parasitaemia increased the parasites were diluted in human
A+ blood (National Health Blood & Transplant, UK) to
maintain a parasitaemia <4% and a haematocrit of 4%.
Early passage stabilates of all seven lines have been de-
posited at the European Malaria Reagent Repository [37]
and are available for general research use.
Anti-plasmodial activity assays
Growth curves were initiated on ring stage parasites with a
final parasitaemia of 0.5% and a haematocrit of 2% in a
200 μL volume within 96-well microtitre plates. Serial two-
or three-fold drug dilutions were first performed across the
plate in duplicate wells and the parasites added thereafter.
The plate was incubated for 48 hrs at 37°C and parasite
growth was measured using the PicoGreen method [38].
Briefly, PicoGreen (Invitrogen, P7581) was diluted 1:200
into a lysis buffer made up of 20 mM Tris, 5 mM EDTA,
0.008% (w/v) saponin and 0.08% Triton X-100 (pH 7.5).
Thereafter, 50 μL of this solution was pipetted into each
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resuspended parasite solution was transferred from the
original growth assay plate into the Picogreen plate and
was mixed well. This plate was kept in the dark for at least
10 min and was read in a Spectramax M3 microplate
reader (Molecular Devices, Berkshire, UK) at an excitation
wavelength of 485 nm and an emission wavelength of
538 nm.
DNA isolation
Parasite genomic DNA was extracted from 200 μL of whole
blood (for patient-derived samples) or 200 μL of packed red
cells (for culture-adapted parasites) using the QIAamp
DNA Blood Mini Kit (Qiagen, UK) as per the manufac-
turer’s instructions. The DNA was stored at −80°C.
Estimating multiplicity of infection
The P. falciparum isolates were assessed for multiplicity of
infection (MOI) by nested PCR analysis of msp1 block 2
(K1, MAD20, RO33) and msp2 block 3 (FC27, 3D7/IC).
These alleles are characterized by conserved regions flanked
by repeat sequences of variable length; size variation within
the alleles can be used to discriminate different parasite
clones by PCR fragment length polymorphism. Previously
designed primer sets were used but with modified cycling
conditions [39], as follows. Nest 1 amplifications were
performed in 25 μL reaction mixture containing 5 μL
DNA, NH4 buffer, 4 mM MgCl2, 1 mM deoxynucleotides
(dNTPs), 0.2 μM forward primer, 0.2 μM reverse primer
and 1 unit of BIOTAQ™ (Bioline, UK). The cycling
conditions were: denaturation at 94°C for 3 min, 30 cycles
of 94°C for 30 sec, 58°C for 1 min and 68°C for 1 min,
followed by a final extension of 5 min at 68°C.
Nest 2 amplifications were performed in a 25 μL reaction
mixture containing 1 μL of nest 1 product diluted 1/10,
NH4 buffer, 4 mM MgCl2, 1 mM dNTPs, 0.2 μM forward
primer, 0.2 μM reverse primer and 1 unit of BIOTAQ. The
cycling conditions were: denaturation at 94°C for 3 min,
30 cycles of 94°C for 30 sec, 61°C for 1 min and 72°C for
1 min, followed by a final extension of 5 min at 72°C.
In order to separate and visualize the amplification
products by electrophoresis, 15 μL of amplification prod-
ucts mixed with loading buffer was loaded onto 2% agar-
ose gels in 0.5% TBE buffer, stained with ethidium
bromide (EtBr). The minimum MOI was calculated to be
the highest observed number of size variants for either
pfmsp1 or pfmsp2 for any sample (Day 0, Day 1, culture-
adapted) of an isolate.
Genotyping of drug resistance markers
pfcrt
The genotype for pfcrt was determined by multiplex
real-time qPCR performed in a Rotorgene RG3000
thermocycler (Corbett Research, Australia), in which asmall segment around codons 72–76 was amplified in the
presence of three dual-labelled probes complementary to
CVMNK (FAM fluorophore), CVIET (JOE fluorophore)
and SVMNT (ROX fluorophore) exactly as described previ-
ously [40,41]. For data analysis, a threshold for each probe
was set manually using the positive and negative controls.
pfmdr1
Amplification of pfmdr1 for sequencing required two
amplicons, as described previously [42], with minor modi-
fications as follows [see Additional file 1]. For fragment 1,
the nest 1 25 μL reaction mixture contained 5 μL DNA,
NH4 buffer, 2 mM MgCl2, 1 mM dNTPs, 0.2 μM of each
primer and 1 unit of BIOTAQ. The cycling conditions
were 94°C for 3 min followed by 30 cycles of 94°C for
30 sec, 55°C for 30 sec, 65°C for 1 min, and then a final
elongation at 65°C for 5 min. The nest 2 reaction contained
1 μL nest 1 product, primers MDR2/1 and NEWREV1 and
other reagents as for the nest 1 reaction. Cycling condi-
tions were 94°C for 3 min followed by 30 cycles of 94°C for
30 sec, 60°C for 30 sec, 65°C for 1 min, and then a final
elongation at 65°C for 5 min. For fragment 2, the nest 1
25 μL reaction mixture contained 5 μL DNA, NH4 buffer,
2 mM MgCl2, 1 mM dNTPs, 0.2 μM of each primer and 1
unit of BIOTAQ. The cycling conditions were 94°C for
3 min followed by 35 cycles of 94°C for 30 sec, 55°C for
30 sec, 68°C for 45 sec, and then a final elongation at 68°C
for 2 min. The nest 2 reaction contained 1 μL of nest 1
product, primers newfr2_F and newfr2_N2R and other re-
agents as for the nest 1 reaction. The cycling conditions
were 94°C for 3 min followed by 35 cycles of 94°C for
30 sec, 55°C for 30 sec, 68°C for 45 sec, and then a final
elongation at 68°C for 2 min. Amplicons were sequenced
using BigDye Terminator v3.1 cycle sequencing kits and
analysis on an ABI 3730 sequencer (Applied Biosystems).
The sequences were analyzed using Geneious R6 software
(Biomatters, New Zealand). Gene copy number for pfmdr1
was determined by real-time qPCR using the DD-CT
method, exactly as described previously [35].
pfdhfr
Amplification of pfdhfr was performed by nested PCR
amplification exactly as described elsewhere [43].
pfdhps
Amplification of pfdhps was performed by nested PCR
amplification and partial sequencing using the amplifica-
tion primers R2 and R/ described by Pearce et al. [43],
with the following modifications. Each 25 μL reaction
mixture contained 5 μL DNA, KCl buffer, 0.2 mM dNTPs,
0.4 μM of each primer and 1 unit of BIOTAQ. The cycling
conditions were 93°C for 5 min followed by 40 cycles of
93°C for 20 sec, 55°C for 30 sec, 68°C for 75 sec, and then
a final elongation at 68°C for 5 min. The nest 2 reaction
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midFWD and midREV [44] and other reagents as for the
nest 1 reaction. The cycling conditions were 93°C for 5 mi-
nutes followed by 30 cycles of 93°C for 20 sec, 56°C for
30 sec, 68°C for 75 sec, and then a final elongation at 72°C
for 5 min.
pfap2mu
Three nested fragments of pfap2mu (gene ID
PF3D7_1218300) were amplified from a single primary
amplicon as described [Hallett RL, Henriques G, Beshir
KB, Gadalla NB, Burrow R, van Schalkwyk DA, Sawa P,
Bousema T, Sutherland CJ: Sub-microscopic Plasmodium
falciparum persisting in Kenyan children immediately
after ACT show directional selection at the pfmdr1, pfcrt,
pfubp-1 and pfap2mu loci, in preparation.], using primers
and conditions provided in the additional file [see
Additional file 1]. Each amplification reaction was per-
formed in a total volume of 25 μL with the following reac-
tion mixture: 0.2 μM of each primer, 4.0 mM MgCl2,
0.4 mM dNTPs and 1 U Bioline Taq polymerase (Bioline,
UK). Extracted DNA (5 μL) was added to each first round
PCR mixture. One microliter of the first round product
was then used as a template in a 25 μL nested amplifica-
tion. The thermal cycle programme for the primary ampli-
fication was 94°C for 3 min, and 30 cycles of 94°C for
30 sec, annealing temperature for 30 sec and 68°C for
1 min with a final extension of 68°C for 15 min. The sec-
ond round of PCR consisted of one initial denaturation
hold at 94°C for 3 min, followed by 40 cycles of 94°C for
30 sec, annealing temperature for 30 sec and 68°C for
45 sec with a final extension of 68°C for 10 min.
Sequencing of PCR products
PCR-amplified products from all loci were purified with
Exonuclease I (ExoI) and Thermosensitive Alkaline Phos-
phatase (AP) enzymes (Fermentas, UK) in order to elimin-
ate non-incorporated dNTPs and primers. The enzymatic
purification was carried out in a final volume of 10 μL
containing 5 μL of the PCR product, 3 U ExoI, 1 U AP
and 1X AP reaction buffer, which were incubated for
60 min at 37°C followed by 15 min at 72°C for enzyme
denaturation.
The cycle sequencing reactions were carried out using
1 μL ExoI/AP purified PCR amplicons, 0.5 μL BigDye®
Terminator v3.1 Cycle Sequencing Kit reaction mix (Ap-
plied Biosystems, UK), 0.2 μM of each PCR primer,
1.75 μL Big Dye Sequencing Buffer (Applied Biosystems)
in a total volume of 10 μL. Single-base extension was
performed as follows: one denaturation hold at 96°C for
1 min followed by 25 cycles of 96°C for 30 sec, 50°C for
15 sec, and 60°C for 4 min.
The sequenced reaction fragments were purified using
ethanol/sodium acetate precipitation method, where3 μL 3 NaOAc (pH 4.6), 62.5 μL 100% ethanol and
24.5 μL of nuclease free water were added to each sample.
The samples were mixed by inversion and incubated
at −20°C for 25 min. After incubation, samples were
centrifuged at 4°C at 3000 g for 30 min. The supernatant
was discarded by inversion, 150 μL ice cold 70% ethanol
was added and the samples centrifuged at 4°C at 3000 g
for 10 min. The supernatant was discarded by inversion
and each sample was allowed to dry at room temperature
for 30 min. Finally, pellets were resuspended in 10 μL Hi-
Di formamide. Samples were fractionated on an ABI prism
3730 Genetic Analyzer (Applied Biosystems). Raw se-
quence data in the form of chromatograms from both
sense and antisense primers were edited, aligned and as-
sembled into contigs using Geneious Pro software (version
5.5.3; Biomatters, New Zealand), after resolving potential
ambiguities by eye. Genetic polymorphisms were identified
by comparing each sequence to that of the 3D7 reference
genome.
Statistics
Plasmodium falciparum sensitivity to anti-malarial com-
pounds in vitro was calculated relative to untreated con-
trol wells of the same parasite line by first subtracting
the background fluorescence (i e, from parasites ex-
posed to a supralethal 10 μM chloroquine concentra-
tion) from all the remaining parasite-containing wells.
The fluorescence signal from each drug-exposed para-
site well was then divided by the average fluorescent sig-
nal from drug-free parasite control wells and converted
to percentage viability. Viability vs concentration was
plotted in SigmaPlot 2000 or Prism v4.02 and curves
generated using sigmoidal dose response functions. The
IC50 values were then extrapolated from these curves
for each drug. Statistical comparisons of the IC50 values
were performed using Student’s two-tailed t-test for
paired or unpaired samples as appropriate.Results
Plasmodium spp. parasites were obtained from travellers
returning to London from several malaria-endemic re-
gions within Africa, between February and October 2012.
Long-term culture was attempted on P. falciparum iso-
lates from seven patients with microscopy-confirmed un-
complicated falciparum malaria, and who gave written
informed consent for inclusion in the study. Seven in vitro
parasite lines were successfully obtained, and each given a
designation of the form HL12XX, for HTD / LSHTM
2012, plus a two-digit serial number. Also receiving HL
designations were five non-falciparum parasite isolates
(two P. vivax, one P. ovale curtisi and one P. malariae)
collected for ex vivo drug sensitivity assays, which will be
reported elsewhere.
van Schalkwyk et al. Malaria Journal 2013, 12:320 Page 6 of 15
http://www.malariajournal.com/content/12/1/320Patient travel histories and treatment
HL1204 - Kenya
This isolate was collected from a UK-resident adult male
of Kenyan origin who had spent three weeks in Nairobi
and coastal Kenya. Symptoms arose two weeks after return
to the UK, and persisted for one week before attending
HTD with 3.6% P. falciparum parasitaemia by microscopy.
Schizonts and gametocytes were seen. Treatment was with
intravenous artesunate due to high parasitaemia and early
indicators of organ dysfunction. Parasitaemia estimates at
18, 45 and 68 hours were 3.2, 0.0001 and 0.001%, respect-
ively, and the patient was discharged at ~72 hours on a full
course of oral artemether-lumefantrine. The pre-treatment
sample was placed into culture within 120 min of collec-
tion. An additional DNA preparation was obtained from
the 18-hour sample.
HL1205 - Nigeria
The donor of this isolate was a UK-resident adult Nigerian
woman who spent two weeks in Lagos with her husband.
On return to the UK, symptoms arose, and the patient
reported taking two tablets of Nivaquine (probably 200 mg
chloroquine-sulphate) four days before presenting to
UCLH with 3.2% peripheral parasitaemia, schizonts being
present in the blood films. The patient received two doses
of intravenous artesunate and, once improved, switched to
a full oral course of artemether-lumefantrine. (The patient’s
husband was also diagnosed with falciparum malaria, hos-
pitalized and treated at the same time as his wife.) Esti-
mates of peripheral parasitaemia at 15, 36 and ~50 hours
were 0.38, 0.0001% and negative, respectively. There was a
16-hour delay between collection of the pre-treatment
sample and initiation of culture. An additional DNA prep-
aration was obtained from the 15-hour sample.
HL1209 – South Sudan
A UK-born UK resident who frequently travels to Africa,
and with a previous history of three treated malaria infec-
tions, presented six days after return from a six-week trip
to South Sudan. Microscopy confirmed 1.6% peripheral P.
falciparum parasitaemia with schizonts present, and the
patient was started on intravenous artesunate. Estimates
of parasitaemia at 13, 37 and 57 hours were 3.2, 0.005%
and negative, respectively. The patient was discharged on
a full oral course of artemether-lumefantrine. There was a
nine-hour delay between collection of the pre-treatment
sample (at 00:45) and its processing for continuous cul-
ture. An additional DNA preparation was obtained from
the 13-hour sample.
HL1210 – Ghana
This isolate was donated by an Indian-born young adult
male, resident in Singapore but studying in the UK. The
subject returned to the UK following a two-week trip toGhana for a college project, and reported purchasing a
course of anti-malarial chemoprophylaxis from a high
street pharmacy in the UK before departure. Described
as “two large tablets taken weekly and two small tablets
taken daily”, this was almost certainly a course of
chloroquine-proguanil, which does not require a prescrip-
tion in the UK, but is no longer considered appropriate
chemoprophylaxis for sub-Saharan Africa [41]. The patient
stated that the course was not completed. He was well
enough to attend a one-day international cricket match
four days after returning to the UK, but developed symp-
toms the following day, which were managed with analge-
sics for three days. On the fourth day of symptoms, a
peripheral P. falciparum parasitaemia of 0.3% was diag-
nosed at HTD, and the patient admitted to UCLH on oral
artemether-lumefantrine. At 15 hours, parasitaemia had
fallen to 0.05%, and the patient had improved sufficiently
to recall the score in the cricket match. At 40 hours, para-
sitaemia was 0.0001% and the patient was discharged. The
pre-treatment sample was collected at 17:45, and sat at
ambient temperature in the laboratory overnight, before
being placed into culture at ~10:00 next morning. An
additional DNA preparation was obtained from the 15-
hour sample.
HL1211 – Ghana
Blood samples from this patient, a young British adult
male, were referred to HTD by an outside hospital in
London, as a suspected case of artemether-lumefantrine
treatment failure. The patient gave retrospective written
signed consent to his physician for inclusion of parasite-
positive samples in the study. Having presented with a P.
falciparum parasitaemia of 0.03%, the patient was treated
with oral artemether-lumefantrine, although it is unknown
whether this was administered with fatty food, as re-
commended. At six hours, parasitaemia had increased to
4.2%, but fallen to 1.1% by 24 hours, and 0.001% by
48 hours. The patient was discharged following a negative
blood film at 72 hours.
Fourteen days later, symptoms recurred, and P. falcip-
arum parasitaemia of 0.7% was confirmed by the on-call
microscopist at HTD, at 21:58 on a Sunday night. This
EDTA vacutainer sample spent 60 hours at 4°C before be-
ing placed into continuous culture. The patient was
treated with oral atovaquone-proguanil, and parasitaemia
fell to 0.4 and then 0.07%, before eventual parasite clear-
ance and a full recovery. An additional DNA preparation
was obtained from the sample with 0.4% parasitaemia.
HL1212 – Nigeria
Blood samples for this isolate were referred to HTD from
a hospital outside London because the patient, an adult
UK resident female who recently travelled to Nigeria, car-
ried an unusual hyper-gametocytaemia, in addition to
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immediate family gave written permission for any viable
malaria parasites to be placed in culture for research. No
post-treatment sample was available for analysis for
this patient.
HL1214 – Burkina Faso
The donor of this isolate was a South African born
adult female, a UK resident, who had spent three days
in Burkina Faso on business. Malaria symptoms began
11 days after returning to London, and a blood sample
taken at 21:46 on the 12th day was found to have 1.0%
P. falciparum parasitaemia. The patient was treated
with oral artemether-lumefantrine, and a single follow-
up blood sample taken at 36 hours; this was negative
and the patient was discharged to complete her oral
chemotherapy at home. The pre-treatment blood sam-
ple was placed into continuous culture approximately
12 hours after collection. An additional DNA prepar-
ation was obtained from the 36-hour (microscopy
negative) sample.
Establishment of cultures and gametocyte production
The first parasite isolate (HL1204) was placed directly
into standard growth medium of RPMI supplemented
with 10% human AB serum. However, these parasites
initially experienced a large decline in parasitaemia and
took several weeks to recover their growth in culture.
When the second isolate was received, the Methods for
Malaria Research protocol was adopted [45] which com-
bines a reduced amount of human serum (2%) with
0.5 g/L of Albumax II in the RPMI growth medium (see
Methods for full details). In this growth medium, most
parasite cultures adapted to in vitro culture without a
marked decline in parasite growth. HL1204 was later
also cultured in this alternative RPMI growth media. All
the P. falciparum parasites received were successfully
adapted to in vitro parasite growth after periods of time
varying from 12 days to nine weeks, and initial stocks were
frozen within approximately two weeks. Isolates were
maintained in culture for no longer than 12 weeks after
thawing in order to minimize the effects on parasite popu-
lations of genetic drift and loss of chromosome fragments.
It was noted that the first isolate, HL1204 from Kenya,
produced gametocytes in culture spontaneously when the
parasitaemia increased beyond 2%. Similarly, HL1205 was
observed to produce scanty gametocytes at high parasit-
aemia in vitro. The gametocyte-producing property of the
HL1204 isolate is currently being used to produce sexual
parasite forms for transmission studies in mosquitoes
(data not shown). Isolate HL1212 was obtained from a pa-
tient with peripheral hypergametocytaemia at the time of
treatment, but after a few weeks of in vitro cultivation,
there was no evidence of this phenotype persisting, asgametocytes were not observed in significant numbers in
the established cultures under standard conditions.
Multiplicity of infection (MoI)
Nested PCR amplification of the P. falciparum merozo-
ite surface protein 1 (pfmsp1) or 2 (pfmsp2) locus was
used to estimate the minimum number of clones present
in the isolates as reported previously [39,46]. DNA sam-
ples for each isolate were obtained before drug treat-
ment of the patients (Day 0) and one-day after drug
treatment (Day 1) for comparison. A further sample was
taken when the parasites were successfully adapted to
grow in culture in order to examine whether the popula-
tion of clones in the isolates had changed from the time
of presentation at Day 0.
Aside from HL1214, the isolates were shown to con-
tain at least four to six clones (Table 2). For the HL1214
isolate from Burkina Faso, a minimum multiplicity of
two clones was estimated before drug treatment (Day 0)
and both were found to persist into the culture adapted
line. Similarly, three other isolates showed the same
number of clones persisting into culture as those ob-
served at presentation; HL1205 (four clones), HL1209
(six clones) and HL1210 (four clones). However, for iso-
lates HL1204 and HL1212 there were fewer clones ob-
served after culture adaptation than at presentation
(Table 2).
Drug treatment had variable effects on the isolate pop-
ulations. Thirty-six hours after drug treatment all para-
sites for HL1214 had been cleared below the level of
detection in the PCR assay. However, all other isolates
still had multiple clones persisting in the sample after
the first 13–20 hours of drug treatment. For three iso-
lates there was no change in the number of clones
detected on Day 1 post-treatment; HL1209 (six clones),
HL1210 (four clones) and HL1211 (three clones). For
two isolates, HL1204 and HL1205, there was an add-
itional clone detected in vivo at Day 1, as has been previ-
ously described for an imported malaria case [47].
Sensitivity to anti-malarial drugs in vitro
The culture-adapted isolates were all tested for their
sensitivity to a range of MMV-supplied anti-malarial
agents using a standard 48-hour drug exposure and then
measuring viability using the fluorescent PicoGreen
method [38]. All the isolates were highly sensitive to
the endoperoxides, dihydroartemisinin and OZ277, with
IC50 values below 5 nM or 2 nM, respectively (Table 3).
When examining the activity of the 4-aminoquinolines,
it was observed that two of the isolates (HL1205 and
HL1210) were resistant to chloroquine with IC50 values
around 150 nM (chloroquine resistance defined as IC50
value >100 nM [48]). Interestingly, the histories of these
two donors indicate that an incomplete course of
Table 2 Multiplicity of infection in clinical isolates
Isolate Sample pfmsp1 pfmsp2 Minimum number of clones*
K1 MAD20 RO33 FC27 IC Per sample Per isolate
HL1204 Kenya Day 0 pre-treatment 0 1 2 0 1 3 4
Day 1 post-treatment 0 2 2 0 1 4
Culture-adapted 0 1 1 0 1 2
HL1205 Nigeria Day 0 pre-treatment 1 0 1 3 1 4 5
Day 1 post-treatment 2 0 1 4 1 5
Culture-adapted 2 0 2 3 1 4
HL1209 South Sudan Day 0 pre-treatment 0 2 2 4 2 6 6
Day 1 post-treatment 0 1 2 4 2 6
Culture-adapted 0 2 2 4 2 6
HL1210 Ghana Day 0 pre-treatment 2 2 0 0 1 4 4
Day 1 post-treatment 2 2 0 0 1 4
Culture-adapted 2 2 0 0 1 4
HL1211 Ghana Day 0 pre-treatment 2 0 0 0 3 3 6
Day 1 post-treatment 2 0 0 0 3 3
Culture-adapted 1 0 2 4 2 6
†HL1212 Nigeria Day 0 pre-treatment 3 2 1 2 1 6 6
Culture-adapted 2 1 0 3 1 4
HL1214 Burkina Faso Day 0 pre-treatment 0 1 1 0 2 2 2
Day 1 post-treatment 0 0 0 0 0 0
Culture-adapted 0 1 1 0 2 2
*The minimum number of clones in each sample was estimated by adding the highest number of bands for each Pfmsp allele.
†No Day 1 post-treatment sample was obtained for HL1212.
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HTD, in both cases.
The five remaining isolates were highly sensitive to
chloroquine (<15 nM) and all seven isolates were sensi-
tive to amodiaquine and piperaquine with IC50 values
below 8 nM or 32 nM, respectively (Table 3). Sensitivity
to desethyl-amodiaquine was not evaluated. Among the
arylaminoalcohol class of compounds HL1210 was the
most sensitive of the isolates to both mefloquine (7.7
nM) and lumefantrine (24 nM). The IC50 values for mef-
loquine in the remaining isolates ranged from 17–36
nM. The cut-off for mefloquine resistance has been pro-
posed to be 30 nM [48] and thus the HL1209 isolate could
be considered resistant by this definition. However, many
of the isolates demonstrate a reduced sensitivity to meflo-
quine with IC50 values above 20 nM. In contrast to the re-
sults obtained for the other arylaminoalcohol compounds,
isolate HL1210 was the least sensitive to quinine (156 nM)
with the IC50 values for the remaining isolates all below 60
nM (Table 3). For the remaining compounds, all seven iso-
lates were sensitive to pyronaridine, with IC50 values
below 4 nM, and all highly sensitive to atovaquone with
IC50 values below 1 nM (Table 3). Lastly, all but one of the
isolates (i e, HL1214, IC50 value = 62 nM) were highly re-
sistant to the dihydrofolate reductase (DHFR) inhibitorpyrimethamine with IC50 values greater than 10 μM
(pyrimethamine resistance defined as an IC50 value >
100 nM [48]).
Of particular interest are in vitro responses to
lumefantrine, as almost all of the contributing patients re-
ceived a course of oral artemether-lumefantrine as part of
their treatment, and one isolate, HL1211, was obtained
from a donor that appeared to have failed treatment on
this combination. Apart from HL1210, all isolates
exhibited quite low in vitro sensitivity to lumefantrine with
IC50 values ranging from 67–119 nM, with the culture-
adapted line from isolate HL1211 in the middle of this
range at 67 nM. This line took many weeks to recover to
sustainable levels in vitro, and the clonal data in Table 2
suggests that very minor genotypes undetectable in the
pre-treatment sample, which was the apparent in vivo
treatment failure from the earlier course of artemether-
lumefantrine, gradually recovered in abundance to pre-
dominate in the adapted line. Separation of the sub-clones
in isolate HL1211 may vary in intrinsic lumefantrine sensi-
tivities, which is “averaged” among them in the bulk
multiclonal culture, thus obscuring any significant lum-
efantrine resistant phenotype. It may also be that in vitro
estimation of lumefantrine sensitivity is a poor correlate of
in vivo treatment response, and to date no validated IC50
Table 3 Sensitivity of the Plasmodium falciparum patient isolates to a panel of anti-malarial compounds
Isolate IC50 values (nM)
Endoperoxides 4-aminoquinolines Arylaminoalcohols Other
DHA OZ277 CQ AQ PIP MQ LUM QUI PND ATV PYR
HL1204 Kenya 2.7 ± 0.4 0.5 ± 0.1 13 ± 2 3.6 ± 0.5 27 ± 4 20 ± 2 119 ± 17 42 ± 10 2.6 ± 0.5 0.7 ± 0.1 >10000
HL1205 Nigeria 3.6 ± 0.7 0.5 ± 0.1 149 ± 10 5.6 ± 0.5 21 ± 4 17 ± 1 105 ± 20 58 ± 7 3.6 ± 0.9 0.7 ± 0.1 >10000
HL1209 South Sudan 4.7 ± 0.6 1.5 ± 0.5 12 ± 1 6.7 ± 1.1 26 ± 3 36 ± 6 110 ± 23 60 ± 7 2.2 ± 0.8 0.2 ± 0.03 >10000
HL1210 Ghana 1.7 ± 0.3 1.1 ± 0.2 150 ± 7 7.4 ± 0.5 16 ± 2 7.7 ± 0.8 24 ± 6 156 ± 17 1.9 ± 0.5 0.4 ± 0.1 >10000
HL1211 Ghana 4.1 ± 0.3 1.1 ± 0.2 12 ± 1 5.8 ± 0.8 31 ± 7 27 ± 3 67 ± 18 50 ± 16 1.7 ± 0.2 0.3 ± 0.04 >10000
HL1212 Nigeria 3.3 ± 0.8 0.6 ± 0.09 12 ± 3 4.2 ± 1.2 27 ± 4 23 ± 3 91 ± 21 22 ± 4 2.6 ± 0.9 0.8 ± 0.04 >10000
HL1214 Burkina Faso 3.3 ± 0.7 0.6 ± 0.07 14 ± 3 4.2 ± 0.3 23 ± 7 23 ± 1 77 ± 28 52 ± 10 1.3 ± 0.6 0.7 ± 0.2 62 ± 25
Laboratory strains
3D7 Netherlands 5.5 ± 1.0 1.1 ± 0.3 15 ± 2 7.6 ± 1.7 14 ± 1 23 ± 3 73 ± 22 53 ± 6 5.0 ± 0.9 0.3 ± 0.2 28 ± 7
K1 Thailand 5.2 ± 0.9 0.8 ± 0.3 374 ± 55 10 ± 3 37 ± 3 6.8 ± 2.9 32 ± 4 289 ± 40 16 ± 5 4.3 ± 1.0 >10000
The abbreviations for the antimalarial compounds are: dihydroartemisinin (DHA), arterolane, synthetic endoperoxide (OZ277), chloroquine (CQ), amodiaquine (AQ),
piperaquine (PIP), mefloquine (MQ), lumefantrine (LUM), quinine (QUI), pyronaridine (PND), atovaquone (ATV) and pyrimethamine (PYR).
The IC50 values are averaged from at least three independent experiments with some repeated on more than ten occasions. All data are presented as mean ± S.E.
M. In several instances, the IC50 values for pyrimethamine exceeded the limits of detection for the concentration range adopted in the experiments and are thus
reported as >10,000 nM.
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established; all of the contributing patients apart from
HL1211 recovered well on artemether-lumefantrine com-
bination therapy, as either sole therapy, or as a follow-on
oral regimen after intravenous artesunate.Genes associated with drug resistance
Pfcrt
Multiplex real-time PCR was used to identify the alleles
at the chloroquine resistance transporter (pfcrt) codons
72–76 for all the isolates with samples taken on Day 0
(pre-treatment), Day 1 (post-treatment) and after culture-
adaptation (Table 4). For both the HL1211 and HL1214
isolates, the wild type CVMNK was the only detectable
haplotype in all samples. This haplotype is associated with
sensitivity to chloroquine [6] and supports the low chloro-
quine IC50 values reported for these isolates in Table 3. In
the HL1205 and HL1210 isolates, which both exhibited
high chloroquine IC50 values, only the chloroquine-
resistant CVIET haplotype was detected for all samples;
as noted above, both isolates are from patients who
reported self-medication with tablets that were almost
certainly chloroquine. The remaining isolates, HL1204,
HL1209 and HL1212 all show a mixed CVMNK/CVIET
haplotype on Day 0 and Day 1 (no data for HL1212 on
Day 1). However, when these isolates are adapted to
grow in culture, only the CQS CVMNK haplotypes are
detected. No SVMNT haplotypes, associated with re-
sistance to amodiaquine and chloroquine, were ob-
served in any of the isolates.Pfmdr1
The isolates were sequenced to look for polymorphisms in
the multidrug resistance gene (pfmdr1) associated with
drug resistance: namely, N86Y, Y184F, S1034C, N1042D
and D1246Y. No changes were observed from the wild
type codons S1034, N1042 and D1246 for any of the iso-
late samples examined (Table 4). All but one isolate
(HL1210; 86Y) harboured the wild type Asn at codon 86.
The HL1212 isolate was the only isolate to harbour a
mixed haplotype in the pre-treatment sample but only a
single haplotype was evident in the HL1212 culture-
adapted sample. Real-time PCR analysis of each the sam-
ples revealed all the isolates possess only a single copy of
the pfmdr1 gene (Table 4).
Pfdhps and Pfdhfr
The isolates were also examined for polymorphisms in the
genes associated with resistance to the antifolate drugs.
Mutations in the dihydropteroate synthase gene, pfdhps,
are responsible for resistance to the anti-malarial sulp-
hadoxine. Important amino acid changes associated with
resistance include I431V, S436A, A437G, K540E, A581G
and A613S. Only one isolate, HL1209, encoded the wild
type amino acids at all six positions in pfdhps (Table 4).
Three isolates (i e, HL1210, HL1212 and HL1214) showed
a single amino acid change, A437G, while two of the
double mutants contained this mutation plus either a
K540E (for HL1204) or S436A (for HL1211). Isolate
HL1205 was unusual as its two amino acid changes did
not include the A437G mutation but instead harboured
the mutations S436F and A613S. Furthermore, HL1205
Table 4 Haplotypes of parasite markers associated with drug resistance
Isolate Sample Haplotype
Pfcrt Pfmdr1 Pfdhps Pfdhfr Pfmdr1
72-76 86, 184, 1034, 1042, 1246 431, 436, 437, 540, 581, 613 16, 50, 51, 59, 108, 140, 164 Gene copy number
Wild type reference CVMNK NYSND ISAKAA ACNCSVI
HL1204 Kenya Day 0 pre-treatment CVMNK / CVIET NFSND ISGEAA ACNRNVI 1
Day 1 post-treatment CVMNK / CVIET NFSND ISGEAA ACNRNVI 1
Culture-adapted CVMNK NFSND ISGEAA ACNRNVI 1
HL1205 Nigeria Day 0 pre-treatment CVIET NYSND IFAKAS ACIRNVI 1
Day 1 post-treatment CVIET NYSND IFAKAS / ISGKAA ACIRNVI 1
Culture-adapted CVIET NYSND IFAKAS ACIRNVI 1
HL1209 South Sudan Day 0 pre-treatment CVMNK / CVIET NFSND ISAKAA ACICNVI 1
Day 1 post-treatment CVMNK / CVIET NFSND ISAKAA ACICNVI 1
Culture-adapted CVMNK NFSND ISAKAA ACICNVI 1
HL1210 Ghana Day 0 pre-treatment CVIET YFSND ISGKAA ACNRNVI / ACIRNVI 1
Day 1 post-treatment CVIET YFSND ISGKAA ACNRNVI / ACIRNVI 1
Culture-adapted CVIET YFSND ISGKAA ACNRNVI / ACIRNVI 1
HL1211 Ghana Day 0 pre-treatment CVMNK NYSND IAGKAA ACIRNVI 1
Day 1 post-treatment CVMNK NYSND IAGKAA ACIRNVI 1
Culture-adapted CVMNK NFSND ISAKAA ACICNVI 1
*HL1212 Nigeria Day 0 pre-treatment CVMNK / CVIET NYSND / NFSND ISGKAA ACIRNVI 1
Culture-adapted CVMNK NFSND ISGKAA ACIRNVI 1
§HL1214 Burkina Faso Day 0 pre-treatment CVMNK NFSND ISGKAA ACNCSVI / ACNRNVI 1
Culture-adapted CVMNK NFSND ISGKAA ACNCSVI / ACNRNVI 1
*No Day 1 post-treatment sample was obtained for HL1212.
§No haplotype data was obtained for the Day 1 post-treatment sample most likely due to complete parasite clearance shortly after drug administration.
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ple, which did include the single mutant A437G (Table 4).
Resistance to pyrimethamine is caused by mutations in
the dihydrofolate reductase gene, pfdhfr, and is associated
with the following amino acid changes: A16V, N51I,
C59R, S108N and I164L. The only isolate carrying the
pyrimethamine sensitive wild type haplotype was HL1214
(Table 4). All the other isolates harboured pyrimethamine
resistance haplotypes and all contained the amino acid
change from a serine to asparigine in codon 108 (S108N)
which has been suggested to be a vital first step in the de-
velopment of mutants with higher levels of pyrimethamine
resistance [49]. The double mutants carried an additional
mutation, changing either an asparigine to isoleucine at
codon 51 (N51I – HL1209) or a cysteine to arginine at
codon 59 (C59R –HL1204, HL1210, HL1214). The triple
mutants contained mutations in all three aforementioned
codons (i e, N51I, C59R and S108N). No mutations were
observed in the amino acids at codons 16, 50, 140 and 146,
which have also been implicated in resistance to pyrimeth-
amine and/or cycloguanil [43,50]. Interestingly, within each
isolate, none of the pfdhfr haplotypes varied among the
pre-treatment, post-treatment or culture-adapted samples.
Pfap2-mu
Sequences for this gene were determined for all available
ex vivo and in vitro parasite preparations. None of the pre-
viously described non-synonymous polymorphisms at co-
dons 146, 160, 199, 233 or 437 of pfap2mu were found in
any parasite line, or in any ex vivo parasite DNA sample.
Some variation was observed in the previously described
poly-Asn tracts which occur between codons 226 and 234,
and between codons 326 and 331 [36]. A synonymous
mutation from A to G at the third position of codon 163
(Glu) was present in HL1209, HL1211 and HL1214, usu-
ally as a mixture of both alleles. However, in HL1211 all
ex vivo parasite isolates carried the GAA form of codon
163, whereas the culture-adapted parasite line appeared to
harbour only GAG alleles.
Discussion
Using the Methods in Malaria Research protocol for cultur-
ing new isolates [45], it was possible to successfully adapt
all seven of the African P. falciparum patient isolates to
in vitro conditions. The parasites grew more readily in the
combination of 0.5% w/v Albumax II with 2% human AB
serum when compared with the HL1204 line initially grown
in 10% human AB serum in the absence of Albumax II.
The African isolates in this study were shown to be
composed of a complex mixture of parasites with a mini-
mum of between two and six clones. This level of com-
plexity is similar to that reported by Robinson et al. [46].
In that study also, patients presenting with malaria to
HTD after travel to Africa were assessed for MOI andfound to harbour complex mixtures of between three and
five clones using both msp1 and msp2 genotyping and
whole genome analysis [46]. Differences in pfmsp1 and
pfmsp2 repertoires were noted between ex vivo isolates
analysed directly, and those from cultures established from
the same sample over time, most notably for HL1211
(Table 2). This can be explained by the stochastic variation
seen in PCR amplification of complex mixtures [50], and
the fact that ex vivo PCR was performed on the equivalent
of 10 μL of peripheral blood, whereas at least 100 times
that volume of blood was used to establish each long-term
culture, and this could easily have harboured additional
genotypes. Examining clonality through PCR amplification
of the msp1 and msp2 loci is subject to error and can only
provide a minimum estimate of MOI [51]. How then does
this observed genetic complexity arise? Polyclonality need
not arise from multiple mosquito bites and can result from
a single sporozoite inoculation, as suggested by studies of
infections in travellers with minimal exposure to infective
bites [46,47]. This genetic complexity in African isolates
represents an important difference from those obtained
from other regions, thereby emphasizing the potential
benefit of establishing multiclonal isolates for in vitro stud-
ies as a more accurate model of the African P. falciparum
infections found in the field. When the culture-adapted
parasites were compared with the original “pre-treatment”
source parasites it was found that in four of the seven iso-
lates, the number of clones detected remained unchanged
after adaptation. Despite the loss of one and two clones in
culture-adapted HL1204 and HL1212, respectively, the
data in Table 2 suggest that the culture conditions adopted
are favourable to support the growth of multiple clones
and that these isolates should therefore maintain their gen-
etic complexity over time.
All the patients in this study were treated with ACT
therapy which consists of a rapid-acting artemisinin-based
compound (artemether) co-formulated with a longer-
acting compound (lumefantrine), although in two cases
this oral regimen followed initial treatment with intraven-
ous artesunate. In only one of the patients (the donor of
HL1214) were the parasites cleared completely within
24 hours of the treatment administration below the detec-
tion level of the nested PCR assay. In the remaining iso-
lates multiple clones remained detectable after treatment,
and in two of the samples (HL1204, HL1205) the number
of parasite clones detected had increased by one compared
with the number observed pre-treatment. Such compli-
cated clonal dynamics during treatment do not imply that
parasites are resistant to anti-malarial agents, but are due
to fluctuations in relative clonal densities which frequently
occur in treated patients [47]. Clones present in the pre-
treatment sample at low density relative to other well-
represented clones in the overall parasite population may
not be amplified sufficiently to enable detection. However,
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after the drug administration, these clones may become
more evident using the nested PCR method.
Drug sensitivity/resistance
The WHO-recommended combination therapy approach
was intended to prevent parasites from developing resist-
ance to the rapid-acting, highly potent but quickly elimi-
nated artemisinin derivatives. All the isolates in this study
were shown to be highly sensitive to dihydroartemisinin
and the synthetic endoperoxide, OZ277. Recently, reports
have emerged of artemisinin resistance characterized by a
“delayed clearance” phenotype in Thailand, Cambodia and
Myanmar [28,30-34]. A conventional 48-hour drug expos-
ure assay was used to assess parasite growth in this study.
Under similar in vitro assay conditions, previous studies
have been unable to detect artemisinin tolerant parasites,
and new assays have been proposed that use a short pulse
exposure to the artemisinin derivative DHA [34,52]. Al-
though it is of interest to screen the isolates presented
here with such assays, a “delayed clearance” phenotype
similar to that seen in Southeast Asia has not yet been
reported in African studies of ACT efficacy in the field.
Most of the culture-adapted isolates (five out of seven)
were sensitive to chloroquine (Table 3), and all five
harboured the CVMNK haplotype at codons 72–76 of
pfcrt (Table 4). A recent study has shown that treatment
with the ACT artemether-lumefantrine (Coartem®) leads
to the selection of parasites with the lysine at codon 76
in Tanzanian parasites [53]. The two CQR isolates were
both confirmed to harbour the CVIET haplotype com-
monly found in Africa and Asia [54]. In countries where
amodiaquine was used as first-line monotherapy for
malaria, the predominant CQR haplotype emerging has
been SVMNT [55]. In Africa however, chloroquine was
preferred to amodiaquine and, not surprisingly, the
SVMNT CQR haplotype found mostly in Asia, South
America and Papua New Guinea was not observed in
these African isolates. Although the CVIET haplotype in
the mixed CVMNK/CVIET pre-treatment isolates (i e,
HL1204, HL1209 and HL1212: Table 4) was not detected
in the culture-adapted isolates, these clones may still be
present but below the level of sensitivity of the assay.
Using chloroquine drug pressure it may be possible to se-
lect for these minor clones in vitro in the culture-adapted
lines. The reason for these CQR clones not thriving from
the mixed CVMNK/CVIET pre-treatment parasites into
culture adaptation may be related to a fitness cost associated
with mutations in the CQR genes, pfcrt and pfmdr1 [56].
Mutations in the pfmdr1 gene have been implicated in
modulating the sensitivity to several classes of anti-malarial
agents including the 4-aminoquinolines, arylaminoalcohols
and endoperoxides [57-59]. Three haplotypes representing
the five codons implicated previously in drug resistance (i e,86, 184, 1034, 1042, and 1246) were identified among the
HL isolates. These were NYSND (wild type), NFSND and
YFSND. While sensitivity to chloroquine has been shown
to be mediated by mutations in both pfcrt and pfmdr1
[6,7,58], the chloroquine IC50 values reported here do not
correlate with any particular pfmdr1 haplotype. Examining
the pfcrt haplotype in these isolates is sufficient to predict
accurately the chloroquine sensitivity for these isolates irre-
spective of changes in pfmdr1.
As with chloroquine, sensitivity to the anti-malarial
quinine has been shown to be modulated by mutations
in both the pfcrt and pfmdr1 genes [58-60]. In contrast
to chloroquine though, the sensitivity to quinine in these
isolates cannot be explained by its pfcrt haplotype alone.
On the other hand, the one isolate showing a reduced sen-
sitivity to quinine (HL1210; IC50 value ≥2.5-fold relative to
all other isolates) was shown to be the only one harbouring
the YFSND haplotype in pfmdr1. This haplotype differs
from the two other pfmdr1 haplotypes observed in the iso-
lates by the presence of Tyr encoded at codon 86. Simi-
larly, the YFSND haplotype found in HL1210 results in the
greatest sensitivity to mefloquine and lumefantrine. All the
remaining isolates with the Asn at codon 86 were less sen-
sitive to mefloquine and lumefantrine (all >2-fold IC50
value relative to HL1210). The prominence of the Asn
observed at codon 86 in these isolates is not surprising. A
previous in vitro study showed that parasites of this
genotype were less sensitive to arylaminoalcohol com-
pounds (e g, mefloquine, lumefantrine) and endoperoxides
(e g, artemisinin) [57]. This might imply that in order to
evade the toxicity of these compounds in vivo, parasites
carrying the asparigine at codon 86 would be selected in
place of those carrying the tyrosine. Indeed, several studies
have confirmed this concerning trend. In several African
countries where Coartem® has been used as first-line treat-
ment for uncomplicated P. falciparum malaria, reports
have emerged that the N86 codon of pfmdr1 is being se-
lected [35,42,61,62]. Furthermore, Mwai et al. reported that
parasites harbouring both the K76 in pfcrt and N86 in
pfmdr1 had higher lumefantrine IC50 values than those
with mutant alleles [63]. This N86 selection then could ex-
plain the high mefloquine and lumefantrine IC50 values
reported in these isolates while the Y86 found in HL1210
is consistent with sensitivity to these compounds.
Multiple copies of the pfmdr1 gene have been linked
to reduced susceptibility to lumefantrine in vitro in Thai
isolates [64]. However, in the limited number of African
isolates reported here, no increases in pfmdr1 copy
number were observed irrespective of their susceptibility
to lumefantrine. This does not rule out a role for pfmdr1
copy number in reduced drug susceptibility in Africa al-
though as it has been observed recently in Sudanese
malaria patients that pfmdr1 amplification was linked to
recurrent infection after treatment with artemether-
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variation in the length of Asn-rich tracts was observed
in the isolates examined. In HL1211 an allele with a vari-
ant codon 163 appeared to be selected in the established
culture line, but this is a synonymous change and is un-
likely to have any direct bearing on drug response.
Pyronaridine, a compound currently in Phase IV clinical
trials as a licensed combination therapy with artesunate
(Pyramax®), is highly potent against all isolates in this study
irrespective of their resistance to chloroquine and pyri-
methamine and altered sensitivity to the arylaminoalcohol
compounds. Previous studies have proposed that CQR
strains exhibit cross-resistance to pyronaridine [65] but re-
cent evidence suggests that pyronaridine remains effective
against CQR strains [66]. The results from the small sample
of isolates provided here suggest that pyronaridine would
be an effective treatment against multiclonal African para-
sites of diverse origin and drug-resistance profiles. Further-
more, the naphthoquinone atovaquone which is marketed
as a fixed combination with proguanil (Malarone), and
widely used for chemoprophylaxis by travellers to malaria-
endemic regions, was highly potent against all the isolates
tested in this study.
The high degree of resistance to the dihydrofolate re-
ductase inhibitor pyrimethamine in all but one of the
isolates (i e, HL1214) probably reflects the widespread use
of the antifolate therapy Fansidar (sulphadoxine/pyrimeth-
amine) as first-line anti-malarial treatment across Africa for
many years preceding the WHO recommendation for using
ACT as first-line treatment. The IC50 values presented for
pyrimethamine (Table 3) are supported by the DHFR hap-
lotypes reported for each isolate in Table 4. As predicted
from its sensitivity to pyrimethamine (62 nM; Table 3),
HL1214 was the only isolate with the wild type 3D7-like
haplotype. Interestingly, a resistant haplotype was also
detected for this isolate suggesting that these parasites are
present probably as a minor population within the isolate
given that there was no effect on increasing the IC50 value
beyond the 100 nM cut-off for resistance. All of the other
resistant isolates contained either a double or triple muta-
tion in pfdhfr that would be expected to result in a “moder-
ate” or “high” level of pyrimethamine resistance,
respectively [48,49,67]. All the resistant isolates harboured
the change from a serine to asparigine in codon 108
(S108N) which has been suggested to be a critical first step
in the development of mutants with higher levels of pyri-
methamine resistance [49]. The double mutants carried
an additional mutation, changing either an asparigine to
isoleucine at codon 51 (N51I – eg., HL1209) or a cyst-
eine to arginine at codon 59 (C59R – e g, HL1204,
HL1210, HL1214) which are expected to result in mod-
erate resistance to pyrimethamine, whereas parasites
with mutations at all three codons (i e, N51I, C59R and
S108N) are expected to display high level pyrimethamineresistance [49]. No mutations were observed in the amino
acids at positions 16, 50, 140 and 164, which have also been
implicated in resistance to pyrimethamine and/or
cycloguanil [43,49].
The anti-malarial agent sulphadoxine, a drug used in com-
bination with pyrimethamine in the drug treatment Fansidar,
was not included in the panel of compounds tested in this
study. However, the dihydropteroate synthase gene (pfdhps)
was sequenced to look for mutations associated with
sulphadoxine resistance. All but one (i e, HL1209) of the iso-
lates contained parasites with the A437G amino acid change.
This polymorphism, alone or in combination with other mu-
tations in pfdhps, predominates in resistant field isolates [68].
When the A437G mutant is combined with the K540E mu-
tation, this double mutant is strongly associated with clinical
Fansidar treatment failure [69]. Interestingly, the HL1209 iso-
late harbours the “sulphadoxine sensitive” pfdhps haplotype
(ISAKAA) but was shown to be carry resistant alleles for
pfdhfr. It has been proposed previously that mutations in
pfdhps occur only once the parasites in the population carry
at least a double mutant allele in pfdhfr [68]. Quintuple mu-
tants with two mutations in pfdhps (A437G, K540E) and
three mutations in pfdhfr (N51I, C59R, S108N) are strongly
associated with Fansidar treatment failure [69]. Isolates
HL1205 and HL1211 both carry the requisite triple muta-
tions in pfdhfr and harbour double mutations in pfdhps but
these double mutations in pfdhps differ from those previ-
ously linked with treatment failure. It is unclear whether
these quintuple mutant variants are as likely to result in clin-
ical failure after Fansidar treatment.
Conclusions
This study describes the establishment in continuous
culture, in vitro drug sensitivity testing and molecular
characterization of a series of multiclonal P. falciparum
isolates taken directly from UK malaria patients follow-
ing recent travel to various malaria-endemic countries in
Africa. These “HL” isolates are available as an open re-
source for studies of drug response, antigenic diversity
and other aspects of parasite biology.
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